To aid clinicians, patients, and families in the best use of modulators, the Cystic Fibrosis Foundation sponsored the creation of guidelines to inform discussions and support decision-making.
Site Search
Most newborns in the United States are screened for CF at birth through newborn
Allergic bronchopulmonary aspergillosis is a hypersensitivity lung disease that results from exposure to Aspergillus fumigatus and occurs primarily in people with asthma or with cystic fibrosis. These guidelines were developed via a consensus conference of experts in 2003.
Chronic infection with P. aeruginosa is associated with increased morbidity and mortality. Effective regimens include antibiotic therapy for newly acquired infection and routine surveillance with oropharyngeal cultures.
Updated from 2003, these guidelines on infection prevention and control for cystic fibrosis provide recommendations for people with CF, their families, and health care providers to help reduce the spread of germs in the clinic and hospital setting, as well as in everyday life.
Enteral tube feedings are an important treatment option in cystic fibrosis when oral intake is not adequate to meet nutritional goals. A multidisciplinary Cystic Fibrosis Foundation panel developed consensus evidence-based guidelines on all aspects of care regarding enteral feeding.
Enteral tube feedings are an important treatment option in cystic fibrosis when oral intake is not adequate to meet nutritional goals. A multidisciplinary Cystic Fibrosis Foundation panel developed consensus evidence-based guidelines on all aspects of care regarding enteral feeding.
Nutritional support is a vital component of care for patients with cystic fibrosis. These recommendations cover caloric intake, dosing for pancreatic enzyme replacement therapy, and monitoring growth in childhood and weight status in patients of all ages.
Normal growth is associated with good lung function in children with CF. The CF Foundation gathered a team of experts to determine the best ways to ensure good nutrition for healthy growth.
Pancreatic insufficiency (PI) remains a significant issue for the majority of individuals with cystic fibrosis. Recommendations include target doses of pancreatic enzyme replacement therapy (PERT) in infants, children, and adolescents.